MedTrace Logo

CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

NCT03504488 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 132

Last updated 2025-01-15

No results posted yet for this study

Summary

The objective of this study is to assess safety and efficacy of CAB-ROR2-ADC in solid tumors

Conditions

Interventions

BIOLOGICAL

CAB-ROR2-ADC

Conditionally active biologic anti-ROR2 antibody drug conjugate

BIOLOGICAL

PD-1 inhibitor

PD-1 inhibitor

Sponsors & Collaborators

  • BioAtla, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-27
Primary Completion
2024-12-30
Completion
2024-12-30
FDA Drug
Yes

Countries

  • United States
  • Greece
  • Hong Kong
  • Poland
  • Spain
  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03504488 on ClinicalTrials.gov